Redux signals and NF-κb activation in T cells

Free Radical Biology and Medicine

Volumn 25, Issue 3, 1998, Pages 346-361

  Ginn Pease, Margaret E ^a   Whisler, Ronald L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Free radicals; Glutathione; I B; NF B; Reactive oxygen species; Redox regulation; Transcription factors

Indexed keywords

GLUTATHIONE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR PROTEIN; REACTIVE OXYGEN METABOLITE; DNA;

AGING; ATHEROSCLEROSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW; T LYMPHOCYTE; TRANSACTIVATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; ARTERIOSCLEROSIS; CHEMISTRY; METABOLISM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGING; ANIMALS; ARTERIOSCLEROSIS; DNA; HUMANS; NF-KAPPA B; OXIDATION-REDUCTION; T-LYMPHOCYTES; TRANS-ACTIVATION (GENETICS);

EID: 0031595201     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00067-7     Document Type: Review

References (179)

1. Barnes P. J., Karin M. Nuclear factor-kappaB a pivotal transcription factor in chronic inflammatory diseases . N. Engl. J. Med. 336:1997;1066-1071.
2. Collins T. Endothelial nuclear factor-kappaB and the initiation of the atherosclerotic lesion. Lab. Invest. 68:1993;499-508.
3. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle P. A., Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest. 97:1996;1715-1722.
4. Chen C. C., Rosenbloom C. L., Anderson D. C., Manning A. M. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J. Immunol. 155:1995;3538-3545.
5. Liao F., Andalibi A., Qiao J. H., Allayee H., Fogelman A. M., Lusis A. J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J. Clin. Invest. 94:1994;877-884.
6. Trebilcock G. U., Ponnappan U. Induction and regulation of NFkappaB during aging role of protein kinases . Clin. Immunol. Immunopathol. 79:1996;87-91.
7. Trebilcock G. U., Ponnappan U. Evidence for lowered induction of nuclear factor kappa B in activated human T lymphocytes during aging. Gerontology. 42:1996;137-146.
8. Nabel G., Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 326:1987;711-713.
9. Kawakami K., Scheidereit C., Roeder R. G. Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc. Natl. Acad. Sci. USA. 85:1988;4700-4704.
10. Bohnlein E., Lowenthal J. W., Siekevitz M., Ballard D. W., Franza B. R., Greene W. C. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell. 53:1988;827-836.
11. Schreck R., Rieber P., Baeuerle P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:1991;2247-2258.
12. Baeuerle P. A., Henkel T. Function and activation of NF-kappa B in the immune system. Ann. Rev. Immunol. 12:1994;141-179.
13. Israel N., Gougerot-Pocidalo M. A., Aillet F., Virelizier J. L. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J. Immunol. 149:1992;3386-3393.
14. Staal F. J., Roederer M., Herzenberg L. A. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 87:1990;9943-9947.
15. Droge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H. P., Roth S., Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8:1994;1131-1138.
16. Flohe L., Brigelius-Flohe R., Saliou C., Traber M. G., Packer L. Redox regulation of NF-Kappa B activation. Free Radic. Biol. Med. 22:1997;1115-1126.
17. Baldwin A. S. Jr. The NF-kappa B and I kappa B proteins new discoveries and insights . Ann. Rev. Immunol. 14:1996;649-683.
18. Baeuerle P. A., Baichwal V. R. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 65:1997;111-137.
19. Kopp E. B., Ghosh S. NF-kappa B and rel proteins in innate immunity. Adv. Immunol. 58:1995;1-27.
20. Kunsch C., Lang R. K., Rosen C. A., Shannon M. F. Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J. Immunol. 153:1994;153-164.
21. LeClair K. P., Blanar M. A., Sharp P. A. The p50 subunit of NF-kappa B associates with the NF-IL6 transcription factor. Proc. Natl. Acad. Sci. USA. 89:1992;8145-8149.
22. Bradley J. R., Johnson D. R., Pober J. S. Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am. J. Pathol. 142:1993;1598-1609.
23. Kilpinen S., Henttinen T., Lahdenpohja N., Hulkkonen J., Hurme M. Signals leading to the activation of NF-kappa B transcription factor are stronger in neonatal than adult T lymphocytes. Scand. J. Immunol. 44:1996;85-88.
24. Schreck R., Albermann K., Baeuerle P. A. Nuclear factor kappa B an oxidative stress-responsive transcription factor of eukaryotic cells (a review) . Free Radic. Res. Commun. 17:1992;221-237.
25. Schmidt K. N., Amstad P., Cerutti P., Baeuerle P. A. Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappa B. Adv. Exp. Med. Biol. 387:1996;63-68.
26. Anderson M. T., Staal F. J., Gitler C., Herzenberg L. A. Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc. Natl. Acad. Sci. USA. 91:1994;11527-11531.
27. Brennan P., O'Neill L. A. Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines evidence against a universal hypothesis involving oxygen radicals . Biochim. Biophys. Acta. 1260:1995;167-175.
28. Galter D., Mihm S., Droge W. Distinct effects of glutathione disulphide on the nuclear transcription factor kappa B and the activator protein-1. Eur. J. Biochem. 221:1994;639-648.
29. Baeuerle P. A. The inducible transcription activator NF-kappa B regulation by distinct protein subunits . Biochim. Biophys. Acta. 1072:1991;63-80.
30. Perkins N. D., Schmid R. M., Duckett C. S., Leung K., Rice N. R., Nabel G. J. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc. Natl. Acad. Sci. USA. 89:1992;1529-1533.
31. Schmid R. M., Liptay S., Betts J. C., Nabel G. J. Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J. Biol. Chem. 269:1994;32162-32167.
32. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell. 47:1986;921-928.
33. Chan A. C., Desai D. M., Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Ann. Rev. Immunol. 12:1994;555-592.
34. Crabtree G. R., Clipstone N. A. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Ann. Rev. Biochem. 63:1994;1045-1083.
35. Ward S. G. CD28 a signalling perspective . Biochem. J. 318:1996;361-377.
36. Sen C. K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
37. Suzuki Y. J., Mizuno M., Packer L. Signal transduction for nuclear factor-kappa B activation. Proposed location of antioxidant-inhibitable step. J. Immunol. 153:1994;5008-5015.
38. Los M., Schenk H., Hexel K., Baeuerle P. A., Droge W., Schulze-Osthoff K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 14:1995;3731-3740.
39. Grilli M., Chiu J. J., Lenardo M. J. NF-kappa B and Rel participants in a multiform transcriptional regulatory system . Int. Rev. Cytol. 143:1993;1-62.
40. Baeuerle P. A., Baltimore D. NF-kappa B ten years after . Cell. 87:1996;13-20.
41. Baeuerle P. A., Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell. 53:1988;211-217.
42. Ghosh S., Gifford A. M., Riviere L. R., Tempst P., Nolan G. P., Baltimore D. Cloning of the p50 DNA binding subunit of NF-kappa B homology to rel and dorsal . Cell. 62:1990;1019-1029.
43. Kieran M., Blank V., Logeat F., Vandekerckhove J., Lottspeich F., Le Bail O., Urban M. B., Kourilsky P., Baeuerle P. A., Israel A. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 62:1990;1007-1018.
44. Gilmore T. D. NF-kappa B, KBF1, dorsal, and related matters. Cell. 62:1990;841-843.
45. Verma I. M., Stevenson J. K., Schwarz E. M., Van Antwerp D., Miyamoto S. Rel/NF-kappa B/I kappa B family intimate tales of association and dissociation . Genes Dev. 9:1995;2723-2735.
46. Nabel G. J., Verma I. M. Proposed NF-kappa B/I kappa B family nomenclature. Genes Dev. 7:1993;2063-2063.
47. Miyamoto S., Verma I. M. Rel/NF-kappa B/I kappa B story. Adv. Cancer Res. 66:1995;255-292.
48. Molitor J. A., Walker W. H., Doerre S., Ballard D. W., Greene W. C. NF-kappa B a family of inducible and differentially expressed enhancer-binding proteins in human T cells . Proc. Natl. Acad. Sci. USA. 87:1990;10028-10032.
49. Urban M. B., Schreck R., Baeuerle P. A. NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J. 10:1991;1817-1825.
50. Rice N. R., MacKichan M. L., Israel A. The precursor of NF-kappa B p50 has I kappa B-like functions. Cell. 71:1992;243-253.
51. Cogswell P. C., Scheinman R. I., Baldwin A. S. Jr. Promoter of the human NF-kappa B p50/p105 gene. Regulation by NF-kappa B subunits and by c-REL. J. Immunol. 150:1993;2794-2804.
52. Fan C. M., Maniatis T. Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature. 354:1991;395-398.
53. Nolan G. P., Baltimore D. The inhibitory ankyrin and activator Rel proteins. Curr. Opin. Genet. Dev. 2:1992;211-220.
54. Schmitz M. L., Baeuerle P. A. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J. 10:1991;3805-3817.
55. Ruben S. M., Dillon P. J., Schreck R., Henkel T., Chen C. H., Maher M., Baeuerle P. A., Rosen C. A. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science. 251:1991;1490-1493.
56. Kunsch C., Ruben S. M., Rosen C. A. Selection of optimal kappa B/Rel DNA-binding motifs interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation . Mol. Cell. Biol. 12:1992;4412-4421.
57. Coleman T. A., Kunsch C., Maher M., Ruben S. M., Rosen C. A. Acquisition of NFKB1-selective DNA binding by substitution of four amino acid residues from NFKB1 into RelA. Mol. Cell. Biol. 13:1993;3850-3859.
58. Sun S. C., Ganchi P. A., Beraud C., Ballard D. W., Greene W. C. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. USA. 91:1994;1346-1350.
59. Ruben S. M., Narayanan R., Klement J. F., Chen C. H., Rosen C. A. Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative. Mol. Cell. Biol. 12:1992;444-454.
60. Muller C. W., Rey F. A., Sodeoka M., Verdine G. L., Harrison S. C. Structure of the NF-kappa B p50 homodimer bound to DNA. Nature. 373:1995;311-317.
61. Kang S. M., Tran A. C., Grilli M., Lenardo M. J. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science. 256:1992;1452-1456.
62. Algarte M., Lecine P., Costello R., Plet A., Olive D., Imbert J. In vivo regulation of interleukin-2 receptor alpha gene transcription by the coordinated binding of constitutive and inducible factors in human primary T cells. EMBO J. 14:1995;5060-5072.
63. Pimentel-Muinos F. X., Mazana J., Fresno M. Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex role of tumor necrosis factor alpha . Eur. J. Immunol. 25:1995;179-186.
64. Mihm S., Galter D., Droge W. Modulation of transcription factor NF kappa B activity by intracellular glutathione levels and by variations of the extracellular cysteine supply. FASEB J. 9:1995;246-252.
65. Matthews J. R., Kaszubska W., Turcatti G., Wells T. N., Hay R. T. Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. Nucleic Acids Res. 21:1993;1727-1734.
66. Mahon T. M., O'Neill L. A. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270:1995;28557-28564.
67. Matthews J. R., Nicholson J., Jaffray E., Kelly S. M., Price N. C., Hay R. T. Conformational changes induced by DNA binding of NF-kappa B. Nucleic Acids Res. 23:1995;3393-3402.
68. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268:1993;11380-11388.
69. Brennan P., O'Neill L. A. 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC. Biochem. J. 320:1996;975-981.
70. Schmitz M. L., Stelzer G., Altmann H., Meisterernst M., Baeuerle P. A. Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. J. Biol. Chem. 270:1995;7219-7226.
71. Baeuerle P. A., Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 242:1988;540-546.
72. Zabel U., Baeuerle P. A. Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA. Cell. 61:1990;255-265.
73. Fujita T., Nolan G. P., Liou H. C., Scott M. L., Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7:1993;1354-1363.
74. Ohno H., Takimoto G., McKeithan T. W. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 60:1990;991-997.
75. McKeithan T. W., Ohno H., Dickstein J., Hume E. Genomic structure of the candidate proto-oncogene BCL3. Genomics. 24:1994;120-126.
76. Blank V., Kourilsky P., Israel A. NF-kappa B and related proteins Rel/dorsal homologies meet ankyrin-like repeats . Trends Biochem. Sci. 17:1992;135-140.
77. Chiao P. J., Miyamoto S., Verma I. M. Autoregulation of I kappa B alpha activity. Proc. Natl. Acad. Sci. USA. 91:1994;28-32.
78. Beg A. A., Baldwin A. S. Jr. The I kappa B proteins multifunctional regulators of Rel/NF-kappa B transcription factors . Genes Dev. 7:1993;2064-2070.
79. Grimm S., Baeuerle P. A. The inducible transcription factor NF-kappa B structure-function relationship of its protein subunits . Biochem J. 290:1993;297-308.
80. Inoue J., Kerr L. D., Rashid D., Davis N., Bose H. R. Jr, Verma I. M. Direct association of pp40/I kappa B beta with rel/NF-kappa B transcription factors role of ankyrin repeats in the inhibition of DNA binding activity . Proc. Natl. Acad. Sci. USA. 89:1992;4333-4337.
81. Urban M. B., Baeuerle P. A. The 65-kD subunit of NF-kappa B is a receptor for I kappa B and a modulator of DNA-binding specificity. Genes Dev. 4:1990;1975-1984.
82. Beg A. A., Ruben S. M., Scheinman R. I., Haskill S., Rosen C. A., Baldwin A. S. Jr. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B a mechanism for cytoplasmic retention . Genes Dev. 6:1992;1899-1913.
83. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 267:1995;1485-1488.
84. Rice N. R., Ernst M. K. In vivo control of NF-kappa B activation by I kappa B alpha. EMBO J. 12:1993;4685-4695.
85. Akira S., Kishimoto T. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv. Immunol. 65:1997;1-46.
86. Beg A. A., Finco T. S., Nantermet P. V., Baldwin A. S. Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha a mechanism for NF-kappa B activation . Mol. Cell. Biol. 13:1993;3301-3310.
87. Riviere Y., Blank V., Kourilsky P., Israel A. Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection. Nature. 350:1991;625-626.
88. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 78:1994;773-785.
89. Ghosh S., Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 344:1990;678-682.
90. Brockman J. A., Scherer D. C., McKinsey T. A., Hall S. M., Qi X., Lee W. Y., Ballard D. W. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol. Cell. Biol. 15:1995;2809-2818.
91. Didonato J. A., Mercurio F., Karin M. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol. Cell. Biol. 15:1995;1302-1311.
92. Li C. C., Dai R. M., Longo D. L. Inactivation of NF-kappa B inhibitor I kappa B alpha ubiquitin-dependent proteolysis and its degradation product . Biochem. Biophys. Res. Commun. 215:1995;292-301.
93. Scherer D. C., Brockman J. A., Chen Z., Maniatis T., Ballard D. W. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc. Natl. Acad. Sci. USA. 92:1995;11259-11263.
94. Baldi L., Brown K., Franzoso G., Siebenlist U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J. Biol. Chem. 271:1996;376-379.
95. Rodriguez M. S., Wright J., Thompson J., Thomas D., Baleux F., Virelizier J. L., Hay R. T., Arenzana-Seisdedos F. Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene. 12:1996;2425-2435.
96. Traenckner E. B., Pahl H. L., Henkel T., Schmidt K. N., Wilk S., Baeuerle P. A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14:1995;2876-2883.
97. Alkalay I., Yaron A., Hatzubai A., Orian A., Ciechanover A., Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 92:1995;10599-10603.
98. Ginn-Pease M. E., Whisler R. L. Optimal NF kappa B mediated transcriptional responses in Jurkat T cells exposed to oxidative stress are dependent on intracellular glutathione and costimulatory signals. Biochem. Biophys. Res. Commun. 226:1996;695-702.
99. Menon S. D., Guy G. R., Tan Y. H. Involvement of a putative protein-tyrosine phosphatase and I kappa B-alpha serine phosphorylation in nuclear factor kappa B activation by tumor necrosis factor. J. Biol. Chem. 270:1995;18881-18887.
100. Pimentel-Muinos F. X., Munoz-Fernandez M. A., Fresno M. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J. Immunol. 152:1994;5714-5722.
101. Muller J. M., Ziegler-Heitbrock H. W., Baeuerle P. A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology. 187:1993;233-256.
102. Zhang D., Zhang N., Wick M. M., Byrn R. A. HIV type 1 protease activation of NF-kappa B within T lymphoid cells. AIDS Res. Hum. Retroviruses. 11:1995;223-230.
103. Brown K., Park S., Kanno T., Franzoso G., Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. USA. 90:1993;2532-2536.
104. Harhaj E. W., Maggirwar S. B., Good L., Sun S. C. CD28 mediates a potent costimulatory signal for rapid degradation of IkappaBbeta which is associated with accelerated activation of various NF-kappa B/Rel heterodimers. Mol. Cell. Biol. 16:1996;6736-6743.
105. Kanno T., Siebenlist U. Activation of nuclear factor-kappa B via T cell receptor requires a Raf kinase and Ca2+ influx. Functional synergy between Raf and calcineurin. J. Immunol. 157:1996;5277-5283.
106. Wingren A. G., Parra E., Varga M., Kalland T., Sjogren H. O., Hedlund G., Dohlsten M. T cell activation pathways B7, LFA-3, and ICAM-1 shape unique T cell profiles . Crit. Rev. Immunol. 15:1995;235-253.
107. el-Hag A., Lipsky P. E., Bennett M., Clark R. A. Immunomodulation by neutrophil myeloperoxidase and hydrogen peroxide differential susceptibility of human lymphocyte functions . J. Immunol. 136:1986;3420-3426.
108. Los M., Droge W., Stricker K., Baeuerle P. A., Schulze-Osthoff K. Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur. J. Immunol. 25:1995;159-165.
109. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:1993;2005-2015.
110. Schreck R., Meier B., Mannel D. N., Droge W., Baeuerle P. A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175:1992;1181-1194.
111. Menon S. D., Qin S., Guy G. R., Tan Y. H. Differential induction of nuclear NF-kappa B by protein phosphatase inhibitors in primary and transformed human cells. Requirement for both oxidation and phosphorylation in nuclear translocation. J. Biol. Chem. 268:1993;26805-26812.
112. Flescher E., Ledbetter J. A., Schieven G. L., Vela-Roch N., Fossum D., Dang H., Ogawa N., Talal N. Longitudinal exposure of human T lymphocytes to weak oxidative stress suppresses transmembrane and nuclear signal transduction. J. Immunol. 153:1994;4880-4889.
113. Lahdenpohja N., Savinainen K., Hurme M. Pre-exposure to oxidative stress decreases the Nuclear Factor-κB-dependent transcription in T lymphocytes. J. Immunol. 160:1998;1354-1358.
114. Sen C. K., Roy S., Packer L. Involvement of intracellular Ca2+ in oxidant-induced NF-kappa B activation. FEBS Lett. 385:1996;58-62.
115. Hazan U., Thomas D., Alcami J., Bachelerie F., Israel N., Yssel H., Virelizier J. L., Arenzana-Seisdedos F. Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription. Proc. Natl. Acad. Sci. USA. 87:1990;7861-7865.
116. Schieven G. L., Mittler R. S., Nadler S. G., Kirihara J. M., Bolen J. B., Kanner S. B., Ledbetter J. A. ZAP-70 tyrosine kinase, CD45, and T cell receptor involvement in UV- and H2O2-induced T cell signal transduction. J. Biol. Chem. 269:1994;20718-20726.
117. Whisler R. L., Goyette M. A., Grants I. S., Newhouse Y. G. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch. Biochem. Biophys. 319:1995;23-35.
118. Schieven G. L., Kirihara J. M., Myers D. E., Ledbetter J. A., Uckun F. M. Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. Blood. 82:1993;1212-1220.
119. Maggirwar S. B., Harhaj E. W., Sun S. C. Regulation of the interleukin-2 CD28-responsive element by NF-ATp and various NF-kappa B/Rel transcription factors. Mol. Cell. Biol. 17:1997;2605-2614.
120. Civil A., Geerts M., Aarden L. A., Verweij C. L. Evidence for a role of CD28RE as a response element for distinct mitogenic T cell activation signals. Eur. J. Immunol. 22:1992;3041-3043.
121. Lai J. H., Horvath G., Subleski J., Bruder J., Ghosh P., Tan T. H. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell Biol. 15:1995;4260-4271.
122. McGuire K. L., Iacobelli M. Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells. J. Immunol. 159:1997;1319-1327.
123. Ghosh P., Tan T. H., Rice N. R., Sica A., Young H. A. The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family c-Rel, p50, and p65 . Proc. Natl. Acad. Sci. USA. 90:1993;1696-1700.
124. Harhaj E. W., Maggirwar S. B., Good L., Sun S. C. CD28 mediates a potent costimulatory signal for rapid degradation of IkappaBbeta which is associated with accelerated activation of various NF-kappa B/Rel heterodimers. Mol. Cell Biol. 16:1996;6736-6743.
125. Costello R., Lipcey C., Algarte M., Cerdan C., Baeuerle P. A., Olive D., Imbert J. Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. Cell Growth Differ. 4:1993;329-339.
126. Chen Z. J., Parent L., Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 84:1996;853-862.
127. Didonato J. A., Hayakawa M., Rothwarf D. M., Zandi E., Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 388:1997;548-554.
128. Marok R., Winyard P. G., Coumbe A., Kus M. L., Gaffney K., Blades S., Mapp P. I., Morris C. J., Blake D. R., Kaltschmidt C., Baeuerle P. A. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum. 39:1996;583-591.
129. Malinin N. L., Boldin M. P., Kovalenko A. V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 385:1997;540-544.
130. Regnier C. H., Song H. Y., Gao X., Goeddel D. V., Cao Z., Rothe M. Identification and characterization of an IkappaB kinase. Cell. 90:1997;373-383.
131. Sun S. C., Maggirwar S. B., Harhaj E. Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. J. Biol. Chem. 270:1995;18347-18351.
132. Traenckner E. B., Pahl H. L., Henkel T., Schmidt K. N., Wilk S., Baeuerle P. A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14:1995;2876-2883.
133. Good L. F., Maggirwar S. B., Kealiher A., Uhlik M., Sun S. C. Multiple structural domains within I kappa B alpha are required for its inducible degradation by both cytokines and phosphatase inhibitors. Biochem. Biophys. Res. Commun. 223:1996;123-128.
134. Okamoto S., Mukaida N., Yasumoto K., Rice N., Ishikawa Y., Horiguchi H., Murakami S., Matsushima K. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J. Biol. Chem. 269:1994;8582-8589.
135. Steffan N. M., Bren G. D., Frantz B., Tocci M. J., O'Neill E. A., Paya C. V. Regulation of IκB alpha phosphorylation by PKC- and Ca(2+)-dependent signal transduction pathways. J. Immunol. 155:1995;4685-4691.
136. Frantz B., Nordby E. C., Bren G., Steffan N., Paya C. V., Kincaid R. L., Tocci M. J., O'Keefe S. J., O'Neill E. A. Calcineurin acts in synergy with PMA to inactivate kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J. 13:1994;861-870.
137. Koong A. C., Chen E. Y., Giaccia A. J. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 54:1994;1425-1430.
138. Secrist J. P., Burns L. A., Karnitz L., Koretzky G. A., Abraham R. T. Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J. Biol. Chem. 268:1993;5886-5893.
139. Imbert V., Peyron J. F., Farahi Far D., Mari B., Auberger P., Rossi B. Induction of tyrosine phosphorylation and T-cell activation by vanadate peroxide, an inhibitor of protein tyrosine phosphatases. Biochem. J. 297:1994;163-173.
140. Imbert V., Rupec R. A., Livolsi A., Pahl H. L., Traenckner E. B., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P. A., Peyron J. F. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell. 86:1996;787-798.
141. Haskill S., Beg A. A., Tompkins S. M., Morris J. S., Yurochko A. D., Sampson-Johannes A., Mondal K., Ralph P., Baldwin A. S. Jr. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell. 65:1991;1281-1289.
142. Schmidt K. N., Amstad P., Cerutti P., Baeuerle P. A. Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. Adv. Exp. Med. Biol. 387:1996;63-68.
143. Ferran C., Millan M. T., Csizmadia V., Cooper J. T., Brostjan C., Bach F. H., Winkler H. Inhibition of NF-kappa B by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem. Biophys. Res. Commun. 214:1995;212-223.
144. Breithaupt T. B., Vazquez A., Baez I., Eylar E. H. The suppression of T cell function and NF(kappa)B expression by serine protease inhibitors is blocked by N-acetylcysteine. Cell Immunol. 173:1996;124-130.
145. MacKichan M. L., Logeat F., Israel A. Phosphorylation of p105 PEST sequence via a redox-insensitive pathway up-regulates processing of p50 NF-KappaB. J. Biol. Chem. 271:1996;6084-6091.
146. Alkalay I., Yaron A., Hatzubai A., Jung S., Avraham A., Gerlitz O., Pashut-Lavon I., Ben-Neriah Y. In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B. Molec. Cell Biol. 15:1995;1294-1301.
147. Suzuki Y. J., Packer L. Inhibition of NF-kappa B activation by vitamin E derivatives. Biochem. Biophys. Res. Commun. 193:1993;277-283.
148. Geng Z., Rong Y., Lau B. H. S-allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Free Radic. Biol. Med. 23:1997;345-350.
149. Suzuki Y. J., Aggarwal B. B., Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem. Biophys. Res. Commun. 189:1992;1709-1715.
150. Meister A., Anderson M. E. Glutathione. Ann. Rev. Biochem. 52:1983;711-760.
151. Suzuki Y. J., Mizuno M., Packer L. Transient overexpression of catalase does not inhibit TNF- or PMA-induced NF-kappa B activation. Biochem. Biophys. Res. Commun. 210:1995;537-541.
152. Goldstone S. D., Fragonas J. C., Jeitner T. M., Hunt N. H. Transcription factors as targets for oxidative signalling during lymphocyte activation. Biochem. Biophys. Acta. 1263:1995;114-122.
153. Toledano M. B., Leonard W. J. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA. 88:1991;4328-4332.
154. Schraufstatter I. U., Hinshaw D. B., Hyslop P. A., Spragg R. G., Cochrane C. G. Glutathione cycle activity and pyridine nucleotide levels in oxidant-induced injury of cells. J. Clin. Invest. 76:1985;1131-1139.
155. Broquist H. P. Buthionine sulfoximine, an experimental tool to induce glutathione deficiency elucidation of glutathione and ascorbate in their role as antioxidants . Nutr. Rev. 50:1992;110-111.
156. Hamilos D. L., Zelarney P., Mascali J. J. Lymphocyte proliferation in glutathione-depleted lymphocytes direct relationship between glutathione availability and the proliferative response . Immunopharmacology. 18:1989;223-235.
157. Suthanthiran M., Anderson M. E., Sharma V. K., Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc. Natl. Acad. Sci. USA. 87:1990;3343-3347.
158. Staal F. J., Roederer M., Herzenberg L. A. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 87:1990;9943-9947.
159. Zabel U., Schreck R., Baeuerle P. A. DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J. Biol. Chem. 266:1991;252-260.
160. Staal F. J., Anderson M. T., Herzenberg L. A. Redox regulation of activation of NF-kappa B transcription factor complex effects of N-acetylcysteine . Methods Enzymol. 252:1995;168-174.
161. Beiqing L., Chen M., Whisler R. L. Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells. J. Immunol. 157:1996;160-169.
162. Eylar E., Rivera-Quinones C., Molina C., Baez I., Molina F., Mercado C. M. N-acetylcysteine enhances T cell functions and T cell growth in culture. Int. Immunol. 5:1993;97-101.
163. Goldstone S. D., Hunt N. H. Redox regulation of the mitogen-activated protein kinase pathway during lymphocyte activation. Biochim. Biophys. Acta. 1355:1997;353-360.
164. Kunsch C., Rosen C. A. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol. Cell Biol. 13:1993;6137-6146.
165. Matsusaka T., Fujikawa K., Nishio Y., Mukaida N., Matsushima K., Kishimoto T., Akira S. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA. 90:1993;10193-10197.
166. DeForge L. E., Preston A. M., Takeuchi E., Kenney J., Boxer L. A., Remick D. G. Regulation of interleukin 8 gene expression by oxidant stress. J. Biol. Chem. 268:1993;25568-25576.
167. Montgomery K. F., Osborn L., Hession C., Tizard R., Goff D., Vassallo C., Tarr P. I., Bomsztyk K., Lobb R., Harlan J. M. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc. Natl. Acad. Sci. USA. 88:1991;6523-6527.
168. Marui N., Offermann M. K., Swerlick R., Kunsch C., Rosen C. A., Ahmad M., Alexander R. W., Medford R. M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Invest. 92:1993;1866-1874.
169. Yu B. P., Yang R. Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Ann. NY Acad. Sci. 786:1996;1-11.
170. Schwarz K. B. Oxidative stress during viral infection a review . Free Radic. Biol. Med. 21:1996;641-649.
171. Muller F. Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection. Free Radic. Biol. Med. 13:1992;651-657.
172. Droge W., Eck H. P., Gmunder H., Mihm S. Requirement for prooxidant and antioxidant states in T cell mediated immune responses. Relevance for the pathogenetic mechanisms of AIDS? Klin. Wochenschr. 69:1991;1118-1122.
173. Staal F. J., Roederer M., Raju P. A., Anderson M. T., Ela S. W., Herzenberg L. A. Antioxidants inhibit stimulation of HIV transcription. AIDS Res. Hum. Retroviruses. 9:1993;299-306.
174. Pace G. W., Leaf C. D. The role of oxidative stress in HIV disease. Free Radic. Biol. Med. 19:1995;523-528.
175. Roederer M., Raju P. A., Mitra D. K., Herzenberg L. A. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J. Clin. Invest. 99:1997;1555-1564.
176. Lee R., Beauparlant P., Elford H., Ponka P., Hiscott J. Selective inhibition of 1 kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology. 234:1997;277-290.
177. Helenius M., Hanninen M., Lehtinen S. K., Salminen A. Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-κB transcription factor in mouse cardiac muscle. J. Mol. Cell Cardiol. 28:1996;487-498.
178. Helenius M., Hanninen M., Lehtinen S. K., Salminen A. Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa B. Biochem. J. 318:1996;603-608.
179. Halliwell B., Gutteridge J. M. Role of free radicals and catalytic metal ions in human disease an overview . Methods Enzymol. 186:1990;1-85.